Dr. Reddy’s Receives USFDA Post-Application Action Letter for Bachupally Biologics Facility
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.
On January 10, 2026, Dr. Reddy’s Laboratories disclosed that, following a pre-approval inspection by the U.S. Food and Drug Administration (USFDA) at its biologics manufacturing facility in Bachupally, Hyderabad conducted in relation to a product application referenced in an earlier communication on September 13, 2025, the company has now received a Post-Application Action Letter (PAAL) from the USFDA concerning its submitted response. The drugmaker said it will work closely with the US regulator and is committed to addressing the queries raised in the PAAL, indicating that timelines for approval of the related biologic product could depend on how swiftly and satisfactorily these issues are resolved, an outcome that may influence its near-term US biologics pipeline and regulatory risk profile for investors and other stakeholders.
The most recent analyst rating on (RDY) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana. It operates in the generics and biosimilars/biologics segment, developing and manufacturing a range of pharmaceutical products for regulated markets including the United States, India and other international geographies, with a growing focus on complex biologics manufacturing out of facilities such as its Bachupally plant in Hyderabad.
Average Trading Volume: 1,131,367
Technical Sentiment Signal: Hold
Current Market Cap: $11.18B
Learn more about RDY stock on TipRanks’ Stock Analysis page.
